ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0384

Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR
Abstract Number: 0007

Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Abstract Number: 2445

Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Abstract Number: 0870

Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis
Abstract Number: 1491

Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 0896

Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1007

Telehealth Conversion: A Strategy for Optimizing Ambulatory Access
Abstract Number: 0810

Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Abstract Number: 1005

Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial
Abstract Number: 1004

Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario
Abstract Number: 2344

Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Abstract Number: L20

Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study
Abstract Number: 0789

Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Abstract Number: 1406

Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data
Abstract Number: 0980

Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].